FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100089717> ?p ?o ?g. }

• W2100089717 endingPage "292" @default.
• W2100089717 startingPage "285" @default.
• W2100089717 abstract "Background Human infection with the avian influenza A H5N1 virus results in disease with a high fatality rate, against which antiviral treatments have limited efficacy. We aimed to investigate the safety, pharmacokinetics, and therapeutic potential of specific polyclonal immunoglobulin equine F(ab')2 fragments raised against influenza A/Vietnam/1194/2004 virus (H5N1 subtype) in healthy volunteers. Methods We did a randomised, double-blind, placebo-controlled, single-centre phase 1 study. In stage 1 (one infusion) and stage 2 (five infusions) of the trial, we randomly assigned healthy male volunteers to receive once-daily intravenous infusions of 0·85 U/kg body weight of F(ab')2 or once-daily saline placebo. Randomisation was done centrally, with one block of four patients and one block for substitutes (three actives, one placebo) in stage 1, and two blocks of six patients (five actives and one placebo) and the same block for substitutes in stage 2. The primary objective was assessment of the clinical and laboratory safety of F(ab')2, which was monitored for 22 days in the group that received one dose (assessments on days 0–2, 4, 8, 15, and 22) and 33 days in the group that received five doses (days 0–6, 8, 10, 12, 19, 26, and 33). A final post-study safety assessment was done at 120 days. We also assessed pharmacokinetic outcomes, and assayed haemagglutination and seroneutralisation activity. Analysis was done according to intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT02295813. Findings We enrolled 16 healthy Asian men between Sept 28 and Dec 28, 2012, and randomly assigned 13 to one or five doses of F(ab')2 and three to placebo. F(ab')2 was well tolerated, and no deaths or serious adverse events occurred. Three patients had mild adverse events (one each of blepharospasm, sinusitis, and pyrexia). The pyrexia (38°C) was regarded as probably related to the infusion, and resolved after 37 min. Our laboratory assessments of blood and urine samples and physical examinations of heart rate, electrocardiogram readings, and weight showed no clinically significant safety issues. Mean peak plasma concentrations were 19·3 μg/mL (SD 3·5) with the one dose schedule and 23·0 μg/mL (4·5) with the five-dose schedule. F(ab')2 were still detectable in plasma on average up to 5 days after five doses. Haemagglutination inhibition was only increased after the third dose, but in-vitro seroneutralisation activity was transiently increased after each of the five doses to concentrations regarded as clinically beneficial in infected patients. Interpretation F(ab')2 showed good safety, tolerability, and therapeutic potential for managing of H5N1 exposed patients. Funding Fab'entech. Human infection with the avian influenza A H5N1 virus results in disease with a high fatality rate, against which antiviral treatments have limited efficacy. We aimed to investigate the safety, pharmacokinetics, and therapeutic potential of specific polyclonal immunoglobulin equine F(ab')2 fragments raised against influenza A/Vietnam/1194/2004 virus (H5N1 subtype) in healthy volunteers. We did a randomised, double-blind, placebo-controlled, single-centre phase 1 study. In stage 1 (one infusion) and stage 2 (five infusions) of the trial, we randomly assigned healthy male volunteers to receive once-daily intravenous infusions of 0·85 U/kg body weight of F(ab')2 or once-daily saline placebo. Randomisation was done centrally, with one block of four patients and one block for substitutes (three actives, one placebo) in stage 1, and two blocks of six patients (five actives and one placebo) and the same block for substitutes in stage 2. The primary objective was assessment of the clinical and laboratory safety of F(ab')2, which was monitored for 22 days in the group that received one dose (assessments on days 0–2, 4, 8, 15, and 22) and 33 days in the group that received five doses (days 0–6, 8, 10, 12, 19, 26, and 33). A final post-study safety assessment was done at 120 days. We also assessed pharmacokinetic outcomes, and assayed haemagglutination and seroneutralisation activity. Analysis was done according to intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT02295813. We enrolled 16 healthy Asian men between Sept 28 and Dec 28, 2012, and randomly assigned 13 to one or five doses of F(ab')2 and three to placebo. F(ab')2 was well tolerated, and no deaths or serious adverse events occurred. Three patients had mild adverse events (one each of blepharospasm, sinusitis, and pyrexia). The pyrexia (38°C) was regarded as probably related to the infusion, and resolved after 37 min. Our laboratory assessments of blood and urine samples and physical examinations of heart rate, electrocardiogram readings, and weight showed no clinically significant safety issues. Mean peak plasma concentrations were 19·3 μg/mL (SD 3·5) with the one dose schedule and 23·0 μg/mL (4·5) with the five-dose schedule. F(ab')2 were still detectable in plasma on average up to 5 days after five doses. Haemagglutination inhibition was only increased after the third dose, but in-vitro seroneutralisation activity was transiently increased after each of the five doses to concentrations regarded as clinically beneficial in infected patients. F(ab')2 showed good safety, tolerability, and therapeutic potential for managing of H5N1 exposed patients." @default.
• W2100089717 created "2016-06-24" @default.
• W2100089717 creator A5000220054 @default.
• W2100089717 creator A5009733885 @default.
• W2100089717 creator A5016604385 @default.
• W2100089717 creator A5017396901 @default.
• W2100089717 creator A5024979920 @default.
• W2100089717 creator A5034643585 @default.
• W2100089717 creator A5040768518 @default.
• W2100089717 creator A5042355300 @default.
• W2100089717 creator A5043829481 @default.
• W2100089717 creator A5072111593 @default.
• W2100089717 creator A5075053251 @default.
• W2100089717 creator A5089091340 @default.
• W2100089717 date "2015-03-01" @default.
• W2100089717 modified "2023-09-26" @default.
• W2100089717 title "Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study" @default.
• W2100089717 cites W1523679951 @default.
• W2100089717 cites W1980257318 @default.
• W2100089717 cites W1982690535 @default.
• W2100089717 cites W1983457685 @default.
• W2100089717 cites W1992484278 @default.
• W2100089717 cites W2010650184 @default.
• W2100089717 cites W2021756338 @default.
• W2100089717 cites W2032470107 @default.
• W2100089717 cites W2044181031 @default.
• W2100089717 cites W2044735406 @default.
• W2100089717 cites W2045278425 @default.
• W2100089717 cites W2051327011 @default.
• W2100089717 cites W2056504172 @default.
• W2100089717 cites W2067897871 @default.
• W2100089717 cites W2068682244 @default.
• W2100089717 cites W2078854509 @default.
• W2100089717 cites W2085978024 @default.
• W2100089717 cites W2089999473 @default.
• W2100089717 cites W2106173155 @default.
• W2100089717 cites W2124040259 @default.
• W2100089717 cites W2124325593 @default.
• W2100089717 cites W2136992485 @default.
• W2100089717 cites W2149087734 @default.
• W2100089717 cites W2155467153 @default.
• W2100089717 cites W2158112812 @default.
• W2100089717 cites W2162384187 @default.
• W2100089717 cites W2162521661 @default.
• W2100089717 cites W3021125815 @default.
• W2100089717 cites W4238892748 @default.
• W2100089717 doi "https://doi.org/10.1016/s1473-3099(14)71072-2" @default.
• W2100089717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25662592" @default.
• W2100089717 hasPublicationYear "2015" @default.
• W2100089717 type Work @default.
• W2100089717 sameAs 2100089717 @default.
• W2100089717 citedByCount "27" @default.
• W2100089717 countsByYear W21000897172015 @default.
• W2100089717 countsByYear W21000897172016 @default.
• W2100089717 countsByYear W21000897172017 @default.
• W2100089717 countsByYear W21000897172018 @default.
• W2100089717 countsByYear W21000897172019 @default.
• W2100089717 countsByYear W21000897172020 @default.
• W2100089717 countsByYear W21000897172021 @default.
• W2100089717 countsByYear W21000897172022 @default.
• W2100089717 countsByYear W21000897172023 @default.
• W2100089717 crossrefType "journal-article" @default.
• W2100089717 hasAuthorship W2100089717A5000220054 @default.
• W2100089717 hasAuthorship W2100089717A5009733885 @default.
• W2100089717 hasAuthorship W2100089717A5016604385 @default.
• W2100089717 hasAuthorship W2100089717A5017396901 @default.
• W2100089717 hasAuthorship W2100089717A5024979920 @default.
• W2100089717 hasAuthorship W2100089717A5034643585 @default.
• W2100089717 hasAuthorship W2100089717A5040768518 @default.
• W2100089717 hasAuthorship W2100089717A5042355300 @default.
• W2100089717 hasAuthorship W2100089717A5043829481 @default.
• W2100089717 hasAuthorship W2100089717A5072111593 @default.
• W2100089717 hasAuthorship W2100089717A5075053251 @default.
• W2100089717 hasAuthorship W2100089717A5089091340 @default.
• W2100089717 hasConcept C112705442 @default.
• W2100089717 hasConcept C126322002 @default.
• W2100089717 hasConcept C142724271 @default.
• W2100089717 hasConcept C168563851 @default.
• W2100089717 hasConcept C197934379 @default.
• W2100089717 hasConcept C203014093 @default.
• W2100089717 hasConcept C204787440 @default.
• W2100089717 hasConcept C2522874641 @default.
• W2100089717 hasConcept C27081682 @default.
• W2100089717 hasConcept C2777546802 @default.
• W2100089717 hasConcept C519248777 @default.
• W2100089717 hasConcept C535046627 @default.
• W2100089717 hasConcept C71924100 @default.
• W2100089717 hasConcept C90924648 @default.
• W2100089717 hasConcept C98274493 @default.
• W2100089717 hasConceptScore W2100089717C112705442 @default.
• W2100089717 hasConceptScore W2100089717C126322002 @default.
• W2100089717 hasConceptScore W2100089717C142724271 @default.
• W2100089717 hasConceptScore W2100089717C168563851 @default.
• W2100089717 hasConceptScore W2100089717C197934379 @default.
• W2100089717 hasConceptScore W2100089717C203014093 @default.
• W2100089717 hasConceptScore W2100089717C204787440 @default.
• W2100089717 hasConceptScore W2100089717C2522874641 @default.
• W2100089717 hasConceptScore W2100089717C27081682 @default.

• next